International Myeloma Workshop | Conferences

STOMP Trial Shows High Activity in R/R Multiple Myeloma With Selinexor Regimen

September 17, 2019

Selinexor plus lenalidomide and dexamethasone, an all-oral triplet, was found to be highly active in patients with relapsed or refractory multiple myeloma, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop. The regimen is also well tolerated and especially active in patients who did not receive lenalidomide prior to the trial.

Melflufen Combo Demonstrates Activity in Patients With R/R Multiple Myeloma and Extramedullary Disease

September 16, 2019

The combination of melflufen and dexamethasone showed antitumor activity in patients with relapsed or refractory multiple myeloma, both in those with and those without extramedullary disease, according to data from the phase II HORIZON study presented at the 17th International Myeloma Workshop.

Daratumumab Plus VRd Improved Depth of Response in Transplant-Eligible, Newly Diagnosed Myeloma

September 15, 2019

The GRIFFIN study showed that the addition of daratumumab to bortezomib, lenalidomide, and dexamethasone, improved stringent complete response in transplant-eligible patients with newly diagnosed multiple myeloma without affecting stem cell mobilization or hematopoietic reconstitution, according to results presented at the 17th International Myeloma Workshop.

Antitumor Activity Observed With Iberdomide in Heavily Pretreated Myeloma

September 15, 2019

Novel agent iberdomide in combination with dexamethasone was safe and demonstrated antitumor activity in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to findings from a phase Ib/IIa trial presented at the 17th International Myeloma Workshop.

Melflufen Plus Dexamethasone Safe and Effective For R/R Multiple Myeloma

September 15, 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.